EQIX vs LAB · P/E 79, rev $9.22B vs rev $174.4M
Equinix Inc (EQIX) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
EQIX currently screens at market cap $74.23B and trailing P/E 79.4. LAB currently screens at market cap $317.1M.
Not investment advice. Open the EQIX and LAB stock pages for the full models.
Not investment advice.